INVESTOR RELATIONS
Latest News
-
May 4, 2022
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT FOR ORTHO-R SOFT TISSUE REPAIR PLATFORM -
April 6, 2022
ORTHO REGENERATIVE TECHNOLOGIES CLOSES OVERSUBSCRIBED NON-BROKERED PRIVATE PLACEMENT FOR $3.2 MILLION -
March 24, 2022
ORTHO REGENERATIVE TECHNOLOGIES TO PARTICIPATE IN THE 2022 VIRTUAL GROWTH CONFERENCE PRESENTED BY MAXIM GROUP LLC AND HOSTED BY M-VEST -
March 21, 2022
ORTHO REGENERATIVE TECHNOLOGIES AMENDS THE TERMS OF ITS $3 MILLION NON-BROKERED PRIVATE PLACEMENT OF UNITS -
March 15, 2022
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES EXECUTIVE LEADERSHIP CHANGES -
February 11, 2022
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES $3 MILLION NON-BROKERED PRIVATE PLACEMENT OF UNITS -
February 7, 2022
ORTHO REGENERATIVE TECHNOLOGIES ENTERS INTO A MATERIAL TRANSFER AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ORTHO-R ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL -
December 21, 2021
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS THIRD QUARTER 2022 RESULTS -
December 13, 2021
ORTHO REGENERATIVE TECHNOLOGIES CLOSES NON-BROKERED $1.05 MILLION PRIVATE PLACEMENT -
December 13, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES U.S. IND CLINICAL HOLD LIFTED BY THE FDA & CLEARANCE TO PROCEED WITH U.S. CLINICAL TRIAL -
November 12, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES FILING OF RESPONSE TO TYPE A MEETING WITH FDA AND NON-BROKERED $1.5 MILLION PRIVATE PLACEMENT -
October 6, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES SUCCESSFUL TYPE A MEETING WITH U.S. FDA ON CMC ELEMENTS FOR WHICH MORE INFORMATION WAS REQUIRED TO CLEAR IND CLINICAL HOLD -
September 30, 2021
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS SECOND QUARTER 2022 RESULTS -
August 20, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES EXTENSION OF FDA CLINICAL HOLD OF ORTHO-R INVESTIGATIONAL NEW DRUG APPLICATION -
July 21, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS -
July 20, 2021
ORTHO REGENERATIVE TECHNOLOGIES SUBMITS FORMAL RESPONSE TO U.S. FDA CLINICAL HOLD -
July 19, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES AMENDMENTS AND EXTENSION OF UNSECURED CONVERTIBLE DEBENTURES AND WARRANTS -
June 29, 2021
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FIRST QUARTER 2022 RESULTS -
June 15, 2021
ORTHO REGENERATIVE TECHNOLOGIES APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS -
June 4, 2021
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES CLINICAL HOLD LETTER FROM THE U.S. FDA -
June 1, 2021
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FOURTH QUARTER AND 2021 YEAR-END RESULTS -
April 6, 2021
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR ORTHO-R -
March 31, 2021
ORTHO REGENERATIVE TECHNOLOGIES SECURES DTC ELIGIBILITY FOR THE TRADING OF ITS SHARES ON THE US OTCQB MARKET -
March 2, 2021
ORTHO REGENERATIVE TECHNOLOGIES WELL-POSITIONED FOR NEXT PHASE OF DEVELOPMENT -
February 24, 2021
ORTHO REGENERATIVE TECHNOLOGIES ADDS PATRICK O’DONNELL TO BOARD OF DIRECTORS -
February 10, 2021
ORTHO REGENERATIVE TECHNOLOGIES LAUNCHES AGORACOM PLATFORM FOR ONLINE INVESTORS OUTREACH -
February 4, 2021
ORTHO REGENERATIVE TECHNOLOGIES RETAINS WESTWICKE ICR AS INVESTOR RELATIONS ADVISORS FOR THE U.S. -
January 5, 2021
ORTHO REGENERATIVE TECHNOLOGIES ENTERS INTO GLOBAL LICENSE WITH HANUMAN PELICAN, INC. -
December 18, 2020
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS THIRD QUARTER 2021 RESULTS -
December 3, 2020
ORTHO REGENERATIVE TECHNOLOGIES COMPLETES NON-BROKERED $3.0 MILLION PRIVATE PLACEMENT -
October 28, 2020
ORTHO REGENERATIVE TECHNOLOGIES BEGINS TRADING ON THE OTCQB U.S. MARKET -
October 19, 2020
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES THE NOMINATION OF ITS NEW VICE-PRESIDENT CLINICAL AND MEDICAL AFFAIRS -
September 25, 2020
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS SECOND QUARTER 2021 RESULTS -
September 2, 2020
ORTHO REGENERATIVE TECHNOLOGIES COMPLETES ADDITIONAL PRIVATE PLACEMENT -
August 31, 2020
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF UNITS -
August 24, 2020
ORTHO REGENERATIVE TECHNOLOGIES CLOSES NON-BROKERED $2.5 MILLION PRIVATE PLACEMENT -
August 6, 2020
Ortho Regenerative Technologies Announces FDA Regulatory Designation and Jurisdictional Assignment for Ortho-R -
July 24, 2020
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF UNITS -
July 23, 2020
ORTHO REGENERATIVE TECHNOLOGIES RELEASES NEW POSITIVE HISTOLOGY RESULTS FROM PIVOTAL PRECLINICAL GLP ROTATOR CUFF TEAR REPAIR EFFICACY STUDY IN LARGE-ANIMAL MODEL -
June 30, 2020
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FIRST QUARTER 2021 RESULTS -
June 22, 2020
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES THE NOMINATION OF A NEW INDEPENDENT CHAIRMAN OF THE BOARD -
May 29, 2020
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FOURTH QUARTER AND 2020 YEAR-END RESULTS -
May 20, 2020
ORTHO REGENERATIVE TECHNOLOGIES ENTERS INTO LICENSING AGREEMENT TO EXPAND THE SCOPE OF ITS TECHNOLOGICAL PLATFORM APPLICATIONS -
April 22, 2020
ORTHO REGENERATIVE TECHNOLOGIES ADVANCES ORTHO-R REGULATORY AND CLINICAL PROJECTS WITH $1.1 MILLION PRIVATE PLACEMENT -
March 12, 2020
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES POSITIVE RESULTS FROM PIVOTAL PRECLINICAL STUDY IN ROTATOR CUFF TEAR REPAIR
